SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt leads the BSE “Health Care” space

01 Mar 2012 Evaluate

Wockhardt is currently trading at Rs 515.85, up by 31.65 points or 6.54% from its previous closing of Rs 484.20 on the BSE.

The scrip opened at Rs 485.00 and has touched a high and low of Rs 526.55 and Rs 476.00 respectively. So far 517227 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 526.55 on 01-Mar-2012 and a 52 week low of Rs 251.25 on 06-Jan-2012.

Last one week high and low of the scrip stood at Rs 526.55 and Rs 455.00 respectively. The current market cap of the company is Rs 5660.57 crore.

The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 7.44% and 18.53% respectively.

The other gainers on BSE “ health Care “ space were Strides Arcolab up by 1.95%, Divis Lab up by 1.54%, Glaxosmithkl Pharmacuticals up by 0.99% and Opto Circuits up by 0.48%.

Drug firm, Wockhardt’s consolidated net profit rose by 50.21% to Rs 212.81 crore in the third quarter ended December 31, 2011, on the back of strong sales in the US market. The company had posted a net profit of Rs 141.67 crore for the corresponding period last fiscal.

Net sales of the company rose by 27.12% to Rs 1,208.67 crore in the quarter ended December 31, 2011, from Rs 950.80 crore in the same period last fiscal.

On a standalone basis, the company posted a net profit of Rs 116.16 crore for the third quarter, as against Rs 66.66 crore for the same period last financial year.

Wockhardt Share Price

1693.00 155.75 (10.13%)
06-May-2026 10:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1829.00
Dr. Reddys Lab 1287.50
Cipla 1344.65
Zydus Lifesciences 925.40
Lupin 2393.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×